Form 4: OrbiMed Advisors Sells NeuroPace Inc (NPCE) Shares in Multiple Transactions

OrbiMed Advisors LLC, a significant shareholder of NeuroPace Inc, has reported the sale of common stock in a series of transactions between April 19 and April 23, 2024.

Summary

• OrbiMed Advisors LLC, along with OrbiMed Capital GP VI LLC, filed a Form 4 detailing changes in beneficial ownership of NeuroPace Inc (NPCE) stock.
• The report indicates the sale of NeuroPace common stock across three transactions.
• On April 19, 2024, 18,253 shares were sold at a price of $14.02 per share.
• On April 22, 2024, 24,609 shares were sold at a price of $14.05 per share.
• On April 23, 2024, 21,791 shares were sold at a price of $14.29 per share.
• Following these transactions, OrbiMed Advisors indirectly holds 3,437,322 shares of NeuroPace Inc.
• OrbiMed Advisors and OrbiMed Capital GP VI LLC disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative as a major shareholder is selling shares, which could indicate a lack of confidence or a strategic shift. However, the transactions are not massive relative to their total holdings.

Negatives

• OrbiMed Advisors, a significant shareholder, is reducing its stake in NeuroPace, which could be interpreted negatively by the market.

Risks

• Continued selling pressure from major shareholders like OrbiMed could negatively impact NPCE's stock price.

Industry Context

Share sales by major holders are common and can be for various reasons, including portfolio rebalancing or profit-taking. The impact on NeuroPace will depend on market perception and overall investor sentiment towards the company.

Stakeholder Impact

• Shareholders may react to the news of OrbiMed's share sales, potentially impacting the stock price.
• The company's management will need to manage investor relations and address any concerns arising from these transactions.

Key Dates